Hemophilia a Therapeutic Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment by DelveInsight

Hemophilia A Therapeutic Pipeline
As per DelveInsight’s assessment, globally, Hemophilia A pipeline constitutes 40+ key companies continuously working towards developing 40+ Hemophilia A treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

(Las Vegas, Nevada, United States) “Hemophilia A Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemophilia A Market.

 The Hemophilia A Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Some of the key takeaways from the Hemophilia A Pipeline Report:

Hemophilia A companies working in the treatment market are Gene Therapies Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceutical, ASC Therapeutics, Ascension, Staidson (Beijing) Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Novo Nordisk, Pfizer, and others, are developing therapies for the Hemophilia A treatment 
Emerging Hemophilia A therapies such as – Research program, P-FVIII-101, ET3 lentiviral gene therapy, NXT007, ASC618, SelectAte, STSP-0601, TQG 203, Mim8, Giroctocogene fitelparvovec, and others are expected to have a significant impact on the Hemophilia A market in the coming years.   
In September 2022, Giroctocogene fitelparvovec is an investigational gene therapy for people with moderately to severely severe haemophilia A, according to a recent announcement from Pfizer and Sangamo Therapeutics. A crucial readout is predicted for the first half of 2024, and all trial sites are scheduled to be operational by the end of 2022.
In June 2022, The second cohort of its Phase I/II B-LIEVE dose confirmation trial of FLT180a in patients with haemophilia B has started receiving doses, according to a release from Freeline Therapeutics Holdings
In May 2022, The FDA has approved the biologics licence application (BLA) filed for etranacogene dezaparvovec for priority review, according to a statement from uniQure. For drugs that, if approved, could significantly improve the safety or efficacy of the treatment, diagnosis, or prevention of serious illnesses when compared to standard applications, a BLA is given priority evaluation
In March 2022, ASC618 was given Fast Track designation by the Food and Drug Administration (FDA) for the treatment of haemophilia A.
In November 2021, The pivotal phase III AFFINE study with giroctocogene fitelparvovec (SB-525 or PF07055480) and the Pfizer/Sangamo haemophilia A gene therapy programme have been placed on clinical hold pending FDA assessment of a proposed protocol revision


Hemophilia A Overview

A genetic bleeding illness termed haemophilia A, often called classical haemophilia, is brought on by low amounts of a bloodprotein called factor VIII. Those who have haemophilia A will bleed more than usual following an operation, dental procedure, or other trauma. This condition might be mild, moderate, or severe. In extreme situations, there may be no injury or perhaps a minor injury followed by massive bleeding.


Get a Free Sample PDF Report to know more about Hemophilia A Pipeline Therapeutic Assessment-



Emerging Hemophilia A Drugs Under Different Phases of Clinical Development Include:

Research program: Gene Therapies Generation Bio
P-FVIII-101: Poseida Therapeutics
AGN-193408: Allergan
OCTA101: Octapharma
ET3 lentiviral gene therapy: Expression Therapeutics
NXT007: Chugai Pharmaceutical
ASC618: ASC Therapeutics
SelectAte: Ascension
STSP-0601: Staidson (Beijing) Biopharmaceuticals
TQG 203: Chia Tai Tianqing Pharmaceutical Group
Mim8: Novo Nordisk
Giroctocogene fitelparvovec: Pfizer


Route of Administration

Hemophilia A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

Molecule Type


Molecule Type

Products have been categorized under various Molecule types, such as

Small molecules
Gene Therapies
Bispecific antibodies
Recombinant proteins
Fusion Proteins
Blood coagulation factor replacements


Hemophilia A Pipeline Therapeutics Assessment

Hemophilia A Assessment by Product Type
Hemophilia A By Stage and Product Type
Hemophilia A Assessment by Route of Administration
Hemophilia A By Stage and Route of Administration
Hemophilia A Assessment by Molecule Type
Hemophilia A by Stage and Molecule Type


DelveInsight’s Hemophilia A Report covers around 40+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration


Further Hemophilia A product details are provided in the report. Download the Hemophilia A pipeline report to learn more about the emerging Hemophilia A therapies


Some of the key companies in the Hemophilia A Therapeutics Market include:

Key companies developing therapies for Hemophilia A are – Intellia tx, Amarna therapeutics, Expression Therapeutics, GC Pharma, Chameleon Biosciences, Pfizer, UBI Pharma, GeneVentiv, Chia Tai Tianqing Pharmaceutical Group, Bayer, ASC Therapeutics, Catalyst Biosciences, Staidson Beijing BioPharmaceuticals, Spark Therapeutics, CSL Behring,  Sanofi, Novo Nordisk, Centessa Pharmaceuticals, OPKO Health, Freeline Therapeutics, Spark Therapeutics, Novo Nordisk, Asklepios BioPharmaceutical, Belief Biomed, ASC Therapeutics, uniQure, Sanofi, Bioverativ, and others.


Hemophilia A Pipeline Analysis:

The Hemophilia A pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia A with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia A Treatment.
Hemophilia A key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hemophilia A Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia A market.


Download Sample PDF Report to know more about Hemophilia A drugs and therapies


Hemophilia A Pipeline Market Drivers

Increasing number of hemophilic patients worldwide, increasing development of novel therapies, increasing diagnostic rate are some of the important factors that are fueling the Hemophilia A Market.


Hemophilia A Pipeline Market Barriers

However, side effects associated with the plasma derived products, high cost of recombinant products and other factors are creating obstacles in the Hemophilia A Market growth.


Scope of Hemophilia A Pipeline Drug Insight    

Coverage: Global
Key Hemophilia A Companies: Gene Therapies Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceutical, ASC Therapeutics, Ascension, Staidson (Beijing) Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Novo Nordisk, Pfizer, and others
Key Hemophilia A Therapies: Research program, P-FVIII-101, ET3 lentiviral gene therapy, NXT007, ASC618, SelectAte, STSP-0601, TQG 203, Mim8, Giroctocogene fitelparvovec, and others
Hemophilia A Therapeutic Assessment: Hemophilia A current marketed and Hemophilia A emerging therapies
Hemophilia A Market Dynamics: Hemophilia A market drivers and Hemophilia A market barriers 


Request for Sample PDF Report for Hemophilia A Pipeline Assessment and clinical trials


Table of Contents


Hemophilia A Report Introduction


Hemophilia A Executive Summary


Hemophilia A Overview


Hemophilia A- Analytical Perspective In-depth Commercial Assessment


Hemophilia A Pipeline Therapeutics


Hemophilia A Late Stage Products (Phase II/III)


Hemophilia A Mid Stage Products (Phase II)


Hemophilia A Early Stage Products (Phase I)


Hemophilia A Preclinical Stage Products


Hemophilia A Therapeutics Assessment


Hemophilia A Inactive Products


Company-University Collaborations (Licensing/Partnering) Analysis


Hemophilia A Key Companies


Hemophilia A Key Products


Hemophilia A Unmet Needs


Hemophilia A Market Drivers and Barriers


Hemophilia A Future Perspectives and Conclusion


Hemophilia A Analyst Views




About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.


About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: